Biopharmacy
Haikou has accelerated the implementation of the “Eight Action Plan” to establish the “National Biopharmaceutical Industry Platform of Haikou Medicine Valley (a national biopharmaceutical industry platform)” and cultivate a “100-Billion-Level Biopharmaceutical Industry Cluster”. The Shanghai Zhangjiang Group - Haikou National Hi-tech Industrial Development Zone two-way incubator was inaugurated, marking the strategic cooperation on an inter-provincial “demonstration park for enclave economic cooperation”. The Hainan National Technology Transfer Center has been officially put in operation, and completing the production of the first batch of “orphan drugs” for the treatment of rare diseases. Bloomage Biotechnology starts operating Hainan’s first GMP cell culture medium production line. Poly Pharm and Huluwa Pharmaceutical has been recognized as one of “China’s Most Investable Pharmaceutical Enterprises”. Haikou has deepened the collaboration on “Lecheng R&D + Haikou Production”, and formed an efficient linkage of “front-end research + middle-end development + back-end application” across the entire biomedical industry chain, attracting a batch of high-quality domestic and foreign enterprises such as Haiping Medical Device Industrial Park, Qilu, Simcere Pharmaceutical and Viatris.
Haiping Group - International Medical Device Park in Haikou National Hi-tech Industrial Development Zone
Located in the Meian Ecological Technology New City of Haikou National Hi-tech Industrial Development Zone, the project covers a total planned area of 230 mu (1 mu = 666.67 m2), with a building area of 390,000 m2. It plans to attract more than 300 medical device enterprises and related supporting enterprises, achieve an annual output value of over 10 billion yuan, and build a symbolic professional medical device park in Haikou characterized by high technology, high output value, and high tax revenue. The project is the fastest-developing park within Haiping Group, featuring “corporate secretary” service, streamlined approval procedure, and immediate construction upon land acquisition. In October 2023, Phase I of the project witnessed the issuance of property certificates for 16 factory buildings, and 80% of the project’s built areas are already open for investment.
Minyin International Holdings Group - R&D and Manufacturing Base for Scientific and Intelligent Medical Devices
Minyin International Holdings Group, a subsidiary of the globally renowned bowling equipment manufacturer, Xima Bowling Equipment Co., Ltd., is investing in building a research and manufacturing base for scientific and intelligent medical devices in the Haikou National High-Tech Industrial Development Zone. The project covers an area of 20 mu (1 mu = 666.67 m2), with a total investment of 300 million yuan. Leveraging the favorable conditions of the Hainan Free Trade Port, the advantageous location of Haikou, and the policies such as “output products produced by encouraged industrial enterprises with imported intermediary products, whose added value exceeds 30% (inclusive) after being processed at the Hainan Free Trade Port, are exempt from import tariffs when entering the rest of China” and “for encouraged industries, enterprises registered in the Hainan Free Trade Port that have a practical operational record are entitled to a reduced corporate tax rate of 15%; and high-end talents and highly-demanded talents employed in the Hainan Free Trade Port are entitled to a 15% cap on personal income tax rate”, the project positions itself to be a R&D and production base for products related to pharmaceuticals, medical device, intelligent robots, and IoT smart manufacturing.
Industrial Policies
Key Hainan Free Trade Port Policies
Provincial and Municipal Support Policies
